408 related articles for article (PubMed ID: 19891681)
1. Iron therapy in chronic kidney disease: current controversies.
Kovesdy CP; Kalantar-Zadeh K
J Ren Care; 2009 Dec; 35 Suppl 2():14-24. PubMed ID: 19891681
[TBL] [Abstract][Full Text] [Related]
2. Iron supplementation in the non-dialysis chronic kidney disease (ND-CKD) patient: oral or intravenous?
Macdougall IC
Curr Med Res Opin; 2010 Feb; 26(2):473-82. PubMed ID: 20014980
[TBL] [Abstract][Full Text] [Related]
3. Iron replacement and supplementation in patients with chronic kidney disease.
Wazny LD; Raymond CB
CANNT J; 2011; 21(4):26-30; quiz 31-2. PubMed ID: 22324122
[TBL] [Abstract][Full Text] [Related]
4. Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease.
Wikström B; Bhandari S; Barany P; Kalra PA; Ladefoged S; Wilske J; Thomsen LL
J Nephrol; 2011; 24(5):589-96. PubMed ID: 21240875
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of a single dose of intravenous ferric carboxymaltose (Ferinject) on anaemia in a pre-dialysis population of chronic kidney disease patients.
Tagboto S; Cropper L; Turner J; Pugh-Clarke K
J Ren Care; 2009 Mar; 35(1):18-23. PubMed ID: 19200274
[TBL] [Abstract][Full Text] [Related]
6. Evolution of iv iron compounds over the last century.
Macdougall IC
J Ren Care; 2009 Dec; 35 Suppl 2():8-13. PubMed ID: 19891680
[TBL] [Abstract][Full Text] [Related]
7. Creative iron management--a practical guide.
Jenkins K
J Ren Care; 2009 Dec; 35 Suppl 2():32-5. PubMed ID: 19891684
[TBL] [Abstract][Full Text] [Related]
8. Comparison of intravenous iron sucrose versus low-molecular-weight iron dextran in chronic kidney disease.
Sinha S; Chiu DY; Peebles G; Kolakkat S; Lamerton E; Fenwick S; Kalra PA
J Ren Care; 2009 Jun; 35(2):67-73. PubMed ID: 19432851
[TBL] [Abstract][Full Text] [Related]
9. Oxidative stress markers in predicting response to treatment with ferric carboxymaltose in nondialysis chronic kidney disease patients.
Prats M; Font R; García C; Muñoz-Cortés M; Cabré C; Jariod M; Romeu M; Giralt M; Martinez-Vea A
Clin Nephrol; 2014 Jun; 81(6):419-26. PubMed ID: 24691014
[TBL] [Abstract][Full Text] [Related]
10. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the safety and efficacy of 3 iron sucrose iron maintenance regimens in children, adolescents, and young adults with CKD: a randomized controlled trial.
Goldstein SL; Morris D; Warady BA
Am J Kidney Dis; 2013 Apr; 61(4):588-97. PubMed ID: 23245582
[TBL] [Abstract][Full Text] [Related]
12. Intravenous iron versus erythropoiesis-stimulating agents: friends or foes in treating chronic kidney disease anemia?
Kalantar-Zadeh K; Streja E; Miller JE; Nissenson AR
Adv Chronic Kidney Dis; 2009 Mar; 16(2):143-51. PubMed ID: 19233073
[TBL] [Abstract][Full Text] [Related]
13. Lost without directions: lessons from the anemia debate and the drive study.
Spiegel DM; Chertow GM
Clin J Am Soc Nephrol; 2009 May; 4(5):1009-10. PubMed ID: 19357246
[TBL] [Abstract][Full Text] [Related]
14. IV iron use in patients with higher serum ferritin: case study on anemia in kidney disease.
Larson K
Nephrol Nurs J; 2008; 35(2):184-93; quiz 194-5. PubMed ID: 18472686
[TBL] [Abstract][Full Text] [Related]
15. Use of intravenous iron supplementation in chronic kidney disease: an update.
Macdougall IC; Geisser P
Iran J Kidney Dis; 2013 Jan; 7(1):9-22. PubMed ID: 23314137
[TBL] [Abstract][Full Text] [Related]
16. Use of erythropoiesis stimulating agents and intravenous iron for cancer and treatment-related anaemia: the need for predictors and indicators of effectiveness has not abated.
Katodritou E; Zervas K; Terpos E; Brugnara C
Br J Haematol; 2008 Jul; 142(1):3-10. PubMed ID: 18430192
[TBL] [Abstract][Full Text] [Related]
17. Iron supplementation and erythropoiesis-stimulatory agents in the treatment of cancer anemia.
Pedrazzoli P; Rosti G; Secondino S; Siena S
Cancer; 2009 Mar; 115(6):1169-73. PubMed ID: 19152436
[TBL] [Abstract][Full Text] [Related]
18. Hepcidin for clinicians.
Young B; Zaritsky J
Clin J Am Soc Nephrol; 2009 Aug; 4(8):1384-7. PubMed ID: 19556376
[TBL] [Abstract][Full Text] [Related]
19. The fascinating but deceptive ferritin: to measure it or not to measure it in chronic kidney disease?
Kalantar-Zadeh K; Kalantar-Zadeh K; Lee GH
Clin J Am Soc Nephrol; 2006 Sep; 1 Suppl 1():S9-18. PubMed ID: 17699375
[TBL] [Abstract][Full Text] [Related]
20. Hyporesponsiveness to erythropoiesis stimulating agents in chronic kidney disease: the many faces of inflammation.
Adamson JW
Adv Chronic Kidney Dis; 2009 Mar; 16(2):76-82. PubMed ID: 19233066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
